Key insights
- An analyst suggests Danaher (DHR) is relatively undervalued, citing its current P/E ratio compared to its 10-year average and highlighting its business model with high customer loyalty and recurring revenue. The recent stock decline is attributed to temporary sector-wide challenges and short-term demand dips. The analyst anticipates a recovery in the life sciences and biotech sectors will benefit Danaher, presenting a potential buying opportunity.
The stock price is now nearly 50% below its all-time high during the COVID pandemic and is at its lowest level in the past five years.
The forward P/E ratio currently stands at 22.38, while the average P/E ratio over the past 10 years is 26.44.
While this isn’t a particularly large discount, I consider the stock relatively undervalued at present, and a P/E ratio in this range has often presented a solid buying opportunity in the past.
They aren’t a company with a classic, massive moat, but I believe they have a good business model with a solid moat:
- High customer loyalty: Their products are often deeply integrated into research and production, making switching very time- and cost-intensive * Recurring revenue: They generate high recurring revenue from consumables, services, and licenses for installed equipment * Danaher Business Systems: their “hidden” competitive advantage. A standardized management system based on lean and data-driven principles that helps the individual subsidiaries of Danaher Corporation operate more efficiently, increase margins, and successfully integrate acquisitions, giving them an operational edge over the competition.
The company has undoubtedly faced a number of challenges in recent years and currently has rather modest growth prospects, but I believe that these issues are largely temporary or cyclical in nature.
The entire life sciences and biotech sector has gone through several difficult years following the COVID boom, which has naturally also affected Danaher.
Since last year, however, these sectors have shown signs of recovery, from which Danaher should also be able to benefit, albeit with a slight delay.
Most recently, they were punished primarily due to short-term issues—for example, in the latest quarterly results, due to a temporary dip in demand for flu and respiratory tests—while the medium- to long-term outlook is viewed as generally positive.
Overall, while Danaher isn’t a classic deep-value play at current levels, I consider it an exciting, high-quality company in a sector with significant future potential, and at the current price, it could be an attractive long-term investment.
There is also potential for strong dividend growth over the long term.
What do you guys think ?